Skip to main content
Premium Trial:

Request an Annual Quote

DxS Doubles R&D Staff

NEW YORK (GenomeWeb News) – British molecular diagnostics firm DxS today said that it has doubled its research and development staff from four to eight during the final quarter of this year.
 
The Manchester-based firm said that it also plans to recruit five more product development scientists within the next month. It said that the increase in staff was due to a “marked rise in demand” for its cancer diagnostic kits.
 
DxS recently launched a PI3K Mutation Test Kit based on its real-time PCR technology, called Scorpions, and its ARMS SNP detection technology. It sells other kits for detection of cancer-related mutations under the TheraScreen brand name.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.